Ustekinumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4328 publications

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: June 23, 2026

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Journal: Minerva gastroenterology

Published: June 19, 2026

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

Journal: mAbs

Published: June 17, 2026

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Journal: Journal of Crohn's & colitis

Published: June 17, 2026

Bridging the gap between guidelines and practice: comparative effectiveness of ustekinumab and vedolizumab in Crohn's disease.

Bridging the gap between guidelines and practice: comparative effectiveness of ustekinumab and vedolizumab in Crohn's disease.

Journal: Proceedings (Baylor University. Medical Center)

Published: June 15, 2026

Comparative efficacy of ustekinumab and vedolizumab in anti-TNF-naive and anti-TNF-exposed patients with Crohn's disease: a matched cohort study.

Comparative efficacy of ustekinumab and vedolizumab in anti-TNF-naive and anti-TNF-exposed patients with Crohn's disease: a matched cohort study.

Journal: Proceedings (Baylor University. Medical Center)

Published: June 08, 2026

Analysis on the efficacy of ustekinumab in the patients with isolated perianal Crohn disease

Analysis on the efficacy of ustekinumab in the patients with isolated perianal Crohn disease

Journal: Zhonghua yi xue za zhi

Published: June 07, 2026

Aspergillus niger Osteomyelitis in an Adolescent Receiving Ustekinumab for Crohn's Disease.

Aspergillus niger Osteomyelitis in an Adolescent Receiving Ustekinumab for Crohn's Disease.

Journal: The Pediatric infectious disease journal

Published: June 03, 2026

Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease.

Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease.

Journal: Journal of gastroenterology

Published: May 31, 2026

Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.

Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.

Journal: Drug delivery

Published: May 29, 2026

Prospective single-center study on efficacy and tolerability of ustekinumab biosimilars in moderate-to-severe psoriasis: short term results.

Prospective single-center study on efficacy and tolerability of ustekinumab biosimilars in moderate-to-severe psoriasis: short term results.

Journal: Italian journal of dermatology and venereology

Published: May 26, 2026

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal: Journal of Crohn's & colitis

Published: May 20, 2026

Showing 1-12 of 4,328

Last Updated: 06/30/2026